Peter Warthoe is one of the co-founders of Qlife but decided a few years ago to step out of the management role to focus more on his scientific projects. Given the company's new lean structure and its focus on supporting its Chinese partner's effort to bring products through clinical trials and to the market in China, Peter Warthoe will take up his role as CSO and focus on achieving this goal. Peter is a biochemist from the University of Copenhagen. He worked in the 1990s under the well-known cancer researcher Michael Strauss at the Danish Cancer Society, where he was a co-inventor of Differential Display (DDRT-PCR), a technology that played an important role in the field of gene expression and the development of GeneChips. After that, he went into the biotech industry and has since worked as an entrepreneur, building several companies.

"We have come a long way with this diagnostic self-testing platform, I am very optimistic about the future. It's a mature platform today, and after some turbulent years where we have seen our American counterparts dissolve, we remain the only company in the world that has a home-use immuno-diagnostic platform of this quality. With the recent advancements on the financial and legal sides, I am confident that we will finally be able to bring clinical-level blood tests into homes in the near future", says Peter Warthoe, CSO of Qlife.

"I am very happy that Peter is back in his old position. Peter has extensive scientific expertise and has been instrumental in building the Egoo Health platform. It's great to have him back so that we together can finalize the job we set out do some years ago", says Thomas Warthoe, CEO of Qlife.